Postpartum Depression Global Market Report 2024

The global postpartum depression market has grown exponentially in recent years. It will grow from $9.17 billion in 2023 to $12.15 billion in 2024 at a compound annual growth rate (CAGR) of 32.5%. The growth in the historic period can be attributed to maternal mental health awareness, research advancements, public health initiatives, increased screenings.

The global postpartum depression market is expected to see exponential growth in the next few years. It will grow to $36.96 billion in 2028 at a compound annual growth rate (CAGR) of 32.1%. The growth in the forecast period can be attributed to telehealth services, pharmacological advancements, maternal mental health legislation, mental health workforce expansion. Major trends in the forecast period include integrated care models, peer support programs, perinatal mental health apps, mental health screening tools.

The surge in postpartum depression cases is poised to be the driving force behind the growth of the postpartum depression market in the foreseeable future. Postpartum depression, a condition characterized by heightened anxiety and often accompanied by physical symptoms, typically emerges following childbirth. It is frequently concomitant with postnatal depression and postpartum anxiety and can manifest at any point during the first year after childbirth. Treatment for postpartum depression often involves psychotherapy, which includes talk therapy or mental health counseling, medication, or a combination of both, contributing to the market's expansion. For example, in May 2022, UVA Medical Center reported that the United States witnessed a steady 7.7% increase in the rates of postpartum depression symptoms between December 2020 and March 2021. Furthermore, in 2021, postpartum depression symptoms escalated in 36 out of the 50 U.S. states as well as the District of Columbia. Consequently, the rise in postpartum depression cases is expected to propel the postpartum depression market.

The burgeoning number of childbirths is anticipated to drive the growth of the postpartum depression market. Childbirth refers to the process of delivering a baby from the mother's uterus, typically through the vaginal canal. The mounting number of childbirths plays a pivotal role in the postpartum depression market since postpartum depression (PPD) is a prevalent mental health condition that can affect women after giving birth. This condition manifests through a broad spectrum of symptoms, including feelings of sadness, anxiety, fatigue, and challenges in forming a bond with the newborn. For instance, in August 2022, data from the Office for National Statistics revealed that in 2021, England and Wales recorded a total of 624,828 live births, marking a 1.8% increase from the 613,936 births reported in 2020. Hence, the escalating number of childbirths is a key driver behind the growth of the postpartum depression market.

The underdiagnosis of postpartum depression hinders the growth of the postpartum depression market during the forecast period. Underdiagnosing postpartum depression (PPD) presents significant challenges for women, resulting in reduced access to treatment, an increased risk of complications, diminished quality of life, added workload for healthcare providers, decreased awareness of PPD, and the perpetuation of stigma surrounding the condition. For instance, a study from January 2023 conducted by Valparaiso University found that 60% of first-time mothers in the study experienced underdiagnosed postpartum depression. Among these individuals, 49% were either frequent or occasional alcohol consumers, and 57% were active smokers during their pregnancy. Therefore, underdiagnosis is a hindrance to the growth of the postpartum depression market.

Companies active in the postpartum depression market are focusing on innovation to maintain their market presence. The need for faster-acting therapies and innovative care delivery methods for postpartum depression has arisen due to the limited treatment options available. For example, in February 2023, Biogen Inc., a U.S.-based biotechnology company, and Sage Therapeutics Inc., a U.S.-based biopharmaceutical company, announced the acceptance of a new drug application (NDA) by the United States Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an experimental medication being investigated as a 14-day, once-daily, fast-acting oral therapy for individuals with MDD and PPD. As a neuroactive steroid, zuranolone functions as a positive allosteric modulator of GABA-A receptors, offering a unique mechanism of action. It is designed to rapidly reset dysregulated neural networks to aid in restoring brain function and, in turn, influence the brain networks responsible for mood, arousal, behavior, and cognition.

In December 2022, Biogen Inc. and Sage Therapeutics Inc. joined forces for an undisclosed amount, aimed at the development and commercialization of drugs for major depressive disorder (MDD), postpartum depression (PPD), as well as other mental disorders, essential tremor, and various neurological conditions. Sage Therapeutics Inc. specializes in the development of therapies for neurological conditions such as depression, PPD, neurology, and neuropsychiatric disorders. This collaboration enhances the prospects for advancing treatments in the field of mental health and neurology.

Major players in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

North America was the largest region in the postpartum depression market in 2023. The regions covered in postpartum depression report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the postpartum depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The main types of postpartum depression include postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum panic disorder, postpartum post-traumatic stress disorder, postpartum psychosis, and others. Postpartum blues is a common but self-limiting condition that occurs shortly after childbirth, featuring symptoms such as mood swings, irritability, and tearfulness. Treatment for postpartum depression involves various approaches, including psychotherapy, medication, supplements, and other therapeutic interventions. These treatments can be administered in different ways, such as orally, through injections, and more. Postpartum depression remedies are available through various distribution channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a range of end-users, including hospitals, specialty clinics, home-care settings, and others.

This report provides postpartum depression market statistics, including postpartum depression industry global market size, regional shares, competitors with a postpartum depression market share, detailed postpartum depression market segments, market trends and opportunities and any further data you may need to thrive in the postpartum depression industry. This postpartum depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The postpartum depression market consists of revenues earned by entities by providing services such as medications, psychotherapy (cognitive behavioral therapy) and support group participation. The market value includes the value of related goods sold by the service provider or included within the service offering. The postpartum depression market also includes the sales of medications such as Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), Bupropion and Tricyclic antidepressants (TCAs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.